Fig 2: In vitro cleavage of cellular Endoglin by thrombin. a Immunofluorescence staining of Endoglin was conducted using the Endoglin/CD105 P4A4-Alexa 488 antibody (green) and vectashield mounting medium with DAPI (blue) after treating ECFC with increasing concentrations of Thr-H (0.01, 0.1 and 1 µM). Observations were carried out using confocal microscopy at 20x magnification. Phase photos at 10x magnification were taken for each condition to confirm the presence of the cell monolayer. b Endoglin fluorescence intensity following ECFC treatment with increasing concentrations of Thr-H (0.01, 0.1 and 1 µM) was quantified using ImageJ software (n = 3). c Plots showing the quantification of Eng fluorescence intensity in ECFC following treatment with 1 µM of Thr-H, alongside the number of nuclei relative to the surface. d Immunofluorescence staining of Eng using the Endoglin/CD105 P4A4-Alexa 488 antibody in different cell types, including HUVECs and MSCs, mounted with Vectashield containing DAPI. HUVECs were additionally stained with VE-Cadherin (VE-CAD) using a Texas Red-conjugated antibody, and MSCs were stained with Phalloidin-Alexa 555 to assess cell integrity after treatment with Thr. e Plots showing the quantification of Eng fluorescence intensity in HUVEC and MSC following treatment with 1 µM of Thr-H, alongside the number of nuclei relative to the surface. f ELISA kit assay results for sEng in supernatants of ECFC, HUVEC and MSC treated or not with 1 µM of Thr-H. The data is presented as mean ± S.D. for a minimum of n = 4. Statistical significance was considered at *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001.

Fig 3: Plasma and serum analysis of patients with preeclampsia. The levels of sEng in (a) plasma and in (b) serum were quantified using an ELISA kit assay in a cohort of 60 patients. This cohort comprised 20 non-pregnant women controls, 20 pregnant women controls, and 20 cases diagnosed with preeclampsia. c Plasma and (d) serum samples from preeclampsia patients diluted to ratios of 1:5, 1:10, or 1:20 and reduced with DDT, were subjected to analysis through SDS-PAGE and Western blot with Endoglin/CD105 polyclonal rabbit antibody (ProteinTech). rEng at 100 ng/mL was used as control. The data is presented as mean ± S.D. Statistical significance was determined at *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001. NS indicates a non-specific band.

Fig 4: Predictive study to identify possible cleavage motifs. a Possible cleavage motifs found by the Profile Specific Scoring Matrix analysis (left column) and their associated score (right column) combined with accessibility (A: highly accessible; PA: partially accessible; B: buried) giving the extent to which each sequence corresponds to the profile extracted from known thrombin cleavage motifs. The scale of the score is arbitrary and the sequences highlighted in bold have significantly higher scores (score > 6) than the others and are accessible on the surface of Eng within the context of its open homodimeric structure. Colored sequences correspond to those later determined experimentally as cleavage sites. b Theoretical model of endoglin showing possible thrombin cleavage sites which corresponds to location of the experimentally determined cleavage sites on the structure of the open Eng. c The top panel shows a theoretical model of thrombin (blue) in complex with the CGGRLQTS sequence of endoglin, obtained by docking. A detailed view of the corresponding putative interaction site is shown in the bottom panel (“zoom”).

Fig 5: Sequencing of thrombin-cleaved endoglin bands. a rEng at a concentration of 20 µg/mL was treated at 37 °C for 1 h with 1 µM of Thr-H. The samples were then resolved by SDS-PAGE and subjected to Coomassie Brilliant Blue staining to identify protein spots for subsequent sequencing. Bands at molecular weights of 60, 40, 20, 10, and 8 kDa were excised, with a minimum of 30 bands at each molecular weight selected for further analysis. Plots showing b the decrease in the percentage of the 70 kDa band, specific to the total rEng band and c the percentage of all cleaved bands obtained by the action of Thr-H on Eng, quantified relatively to the total rEng (70 kDa). The optical densities of each Coomassie blue-stained protein band were measured using Image Studio™ Lite software. The data is presented as mean ± S.D. from a minimum of 12 conducted experiments. Statistical significance was considered at *P < 0.05. d Table showing the N-terminal and C-terminal parts of each sequenced band, along with the cleavage position and the cleaved amino acids. The C-terminal information was not determined (ND) for the 8, 40 and 60 kDa bands, and the cleavage position and cleaved amino acids for the last two bands were also unidentified. However, based on the docking data and the Western blot analysis with the monoclonal antibody MAB1097 (R&D), that specifically labels the endoglin orphan region, for we can postulate that the 40 KDa band corresponds to the fragment 329–330. e Schematic diagram illustrating the N-terminal cleavage positions and sequences of each band, including known (solid line) and hypothetical (dashed line) C-terminal cleavages. Because the contribution of glycosylation to the molecular weight of each band is unknown, the correlation between molecular weight and primary structure is not to scale. f Schematic diagram of mEng, indicating cleavage sites. mEng is composed of an orphan region followed by a juxtamembrane zona pellucida (ZP) module and by transmembrane and short cytoplasmic domains. JM: Juxtamembrane; TM: Transmembrane; CP: Cytoplasmic.